{"id":21599,"date":"2025-04-15T14:59:26","date_gmt":"2025-04-15T18:59:26","guid":{"rendered":"https:\/\/thespanishmedia.com\/?p=21599"},"modified":"2025-04-15T14:59:26","modified_gmt":"2025-04-15T18:59:26","slug":"pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico","status":"publish","type":"post","link":"https:\/\/thespanishmedia.com\/pt\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/","title":{"rendered":"Pfizer abandona desarrollo de p\u00edldora experimental para bajar de peso tras caso de posible da\u00f1o hep\u00e1tico"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Pfizer anunci\u00f3 el lunes que ha decidido descontinuar el desarrollo de su p\u00edldora experimental para bajar de peso, danuglipr\u00f3n, luego de que un participante en los ensayos cl\u00ednicos presentara una posible lesi\u00f3n hep\u00e1tica inducida por el medicamento.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">La farmac\u00e9utica hab\u00eda estado evaluando una versi\u00f3n de administraci\u00f3n oral una vez al d\u00eda, despu\u00e9s de cancelar a finales de 2023 el desarrollo de una versi\u00f3n de dos tomas diarias debido a la alta tasa de abandono en un ensayo de fase intermedia. Los pacientes reportaron efectos secundarios como n\u00e1useas y v\u00f3mitos frecuentes.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">El danuglipr\u00f3n hab\u00eda sido considerado una potencial alternativa oral en el creciente y altamente competitivo mercado de medicamentos para la p\u00e9rdida de peso, actualmente dominado por los tratamientos inyectables semanales Wegovy (Novo Nordisk) y Zepbound (Eli Lilly). Se estima que este segmento alcanzar\u00e1 los 150.000 millones de d\u00f3lares en ventas en los pr\u00f3ximos a\u00f1os, atrayendo el inter\u00e9s de empresas farmac\u00e9uticas e inversores.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Pfizer explic\u00f3 que los estudios de optimizaci\u00f3n de dosis mostraron que, en general, las elevaciones de enzimas hep\u00e1ticas entre los 1.400 participantes eran comparables a las observadas con otros medicamentos aprobados de la misma clase. No obstante, la compa\u00f1\u00eda opt\u00f3 por suspender el programa tras analizar los datos cl\u00ednicos y recibir comentarios de los organismos reguladores.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Evan Seigerman, analista de BMO Capital Markets, se\u00f1al\u00f3 que esta decisi\u00f3n deja a Pfizer en una situaci\u00f3n inicial dentro del segmento de la obesidad, ya que sus otros candidatos se encuentran en fases tempranas de investigaci\u00f3n. Sugiri\u00f3 que la compa\u00f1\u00eda podr\u00eda explorar alianzas o adquisiciones en el corto plazo.<\/span><\/p>\n<h2><b>Efecto en el sector econ\u00f3mico<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">El impacto en el mercado burs\u00e1til fue inmediato: las acciones de empresas m\u00e1s peque\u00f1as en el desarrollo de terapias contra la obesidad, como Viking Therapeutics y Structure Therapeutics, subieron entre un 8% y un 10%. Por su parte, las acciones de Eli Lilly subieron un 2,6% y las de Novo Nordisk, que cotizan en Copenhague, m\u00e1s del 3%. Pfizer, en cambio, registr\u00f3 un incremento de apenas 1%, por debajo del alza del 1,5% del \u00edndice S&amp;P 500.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Pfizer afirm\u00f3 que continuar\u00e1 con el desarrollo de otros tratamientos experimentales, incluidos los que se dirigen a la hormona GIPR, y seguir\u00e1 invirtiendo en investigaciones relacionadas con la obesidad. Adem\u00e1s, inform\u00f3 que los datos completos del programa cl\u00ednico con danuglipr\u00f3n ser\u00e1n presentados en una pr\u00f3xima reuni\u00f3n cient\u00edfica o enviados para su publicaci\u00f3n en una revista especializada.<\/span><\/p>\n<p><b>Redacci\u00f3n de: <\/b><span style=\"font-weight: 400;\">Karen Rodr\u00edguez A.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Pfizer anunci\u00f3 el lunes que ha decidido descontinuar el desarrollo de su p\u00edldora experimental para bajar de peso, danuglipr\u00f3n, luego de que un participante en los ensayos cl\u00ednicos presentara una posible lesi\u00f3n hep\u00e1tica inducida por el medicamento. La farmac\u00e9utica hab\u00eda estado evaluando una versi\u00f3n de administraci\u00f3n oral una vez al d\u00eda, despu\u00e9s de cancelar a [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":21604,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_glsr_average":0,"_glsr_ranking":0,"_glsr_reviews":0,"footnotes":""},"categories":[6],"tags":[6687,6688,4795,6689,6690,6691,6692,3171,482,6693,6694,6695,224,6696,204],"class_list":["post-21599","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notas-para-curiosos","tag-danohepatico","tag-danuglipron","tag-ensayosclinicos","tag-farmaceuticas","tag-industriafarmaceutica","tag-medicinaexperimental","tag-medicinaysalud","tag-noticiasdesalud","tag-obesidad","tag-perdidadepeso","tag-pfizer","tag-pfizer2025","tag-saludpublica","tag-tratamientoobesidad","tag-salud"],"blocksy_meta":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.2 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer abandona desarrollo de p\u00edldora experimental para bajar de peso tras caso de posible da\u00f1o hep\u00e1tico - The Spanish Media<\/title>\n<meta name=\"description\" content=\"Pfizer anunci\u00f3 el lunes que ha decidido descontinuar el desarrollo de su p\u00edldora experimental para bajar de peso\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/thespanishmedia.com\/pt\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer abandona desarrollo de p\u00edldora experimental para bajar de peso tras caso de posible da\u00f1o hep\u00e1tico\" \/>\n<meta property=\"og:description\" content=\"Pfizer anunci\u00f3 el lunes que ha decidido descontinuar el desarrollo de su p\u00edldora experimental para bajar de peso\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thespanishmedia.com\/pt\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/\" \/>\n<meta property=\"og:site_name\" content=\"The Spanish Media\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/thespanishmedia.ca\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T18:59:26+00:00\" \/>\n<meta name=\"author\" content=\"The Spanish Media\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"The Spanish Media\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/\"},\"author\":{\"name\":\"The Spanish Media\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#\\\/schema\\\/person\\\/cdfd443208fa68f9cec21cb44a66c134\"},\"headline\":\"Pfizer abandona desarrollo de p\u00edldora experimental para bajar de peso tras caso de posible da\u00f1o hep\u00e1tico\",\"datePublished\":\"2025-04-15T18:59:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/\"},\"wordCount\":458,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"#Da\u00f1oHep\u00e1tico\",\"#Danuglipron\",\"#ensayosCl\u00ednicos\",\"#Farmac\u00e9uticas\",\"#IndustriaFarmac\u00e9utica\",\"#MedicinaExperimental\",\"#MedicinaYSalud\",\"#NoticiasDeSalud\",\"#Obesidad\",\"#P\u00e9rdidaDePeso\",\"#Pfizer\",\"#Pfizer2025\",\"#SaludP\u00fablica\",\"#TratamientoObesidad\",\"salud\"],\"articleSection\":[\"Notas para Curiosos\"],\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/\",\"url\":\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/\",\"name\":\"Pfizer abandona desarrollo de p\u00edldora experimental para bajar de peso tras caso de posible da\u00f1o hep\u00e1tico - The Spanish Media\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2025-04-15T18:59:26+00:00\",\"description\":\"Pfizer anunci\u00f3 el lunes que ha decidido descontinuar el desarrollo de su p\u00edldora experimental para bajar de peso\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/thespanishmedia.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer abandona desarrollo de p\u00edldora experimental para bajar de peso tras caso de posible da\u00f1o hep\u00e1tico\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#website\",\"url\":\"https:\\\/\\\/thespanishmedia.com\\\/\",\"name\":\"The Spanish Media\",\"description\":\"Noticias en espa\u00f1ol, inmigraci\u00f3n y settlement en Canad\u00e1.\",\"publisher\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/thespanishmedia.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#organization\",\"name\":\"The Spanish Media\",\"url\":\"https:\\\/\\\/thespanishmedia.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/thespanishmedia.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Logo-Horizontal.png\",\"contentUrl\":\"https:\\\/\\\/thespanishmedia.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Logo-Horizontal.png\",\"width\":1840,\"height\":720,\"caption\":\"The Spanish Media\"},\"image\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/thespanishmedia.ca\",\"https:\\\/\\\/www.instagram.com\\\/thespanishmedia.ca\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@TheSpanishMedia-\",\"https:\\\/\\\/www.tiktok.com\\\/@thespanishmedia\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#\\\/schema\\\/person\\\/cdfd443208fa68f9cec21cb44a66c134\",\"name\":\"The Spanish Media\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g\",\"caption\":\"The Spanish Media\"},\"url\":\"https:\\\/\\\/thespanishmedia.com\\\/pt\\\/author\\\/media\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer abandona desarrollo de p\u00edldora experimental para bajar de peso tras caso de posible da\u00f1o hep\u00e1tico - The Spanish Media","description":"Pfizer anunci\u00f3 el lunes que ha decidido descontinuar el desarrollo de su p\u00edldora experimental para bajar de peso","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/thespanishmedia.com\/pt\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/","og_locale":"pt_PT","og_type":"article","og_title":"Pfizer abandona desarrollo de p\u00edldora experimental para bajar de peso tras caso de posible da\u00f1o hep\u00e1tico","og_description":"Pfizer anunci\u00f3 el lunes que ha decidido descontinuar el desarrollo de su p\u00edldora experimental para bajar de peso","og_url":"https:\/\/thespanishmedia.com\/pt\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/","og_site_name":"The Spanish Media","article_publisher":"https:\/\/www.facebook.com\/thespanishmedia.ca","article_published_time":"2025-04-15T18:59:26+00:00","author":"The Spanish Media","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"The Spanish Media","Tempo estimado de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/#article","isPartOf":{"@id":"https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/"},"author":{"name":"The Spanish Media","@id":"https:\/\/thespanishmedia.com\/#\/schema\/person\/cdfd443208fa68f9cec21cb44a66c134"},"headline":"Pfizer abandona desarrollo de p\u00edldora experimental para bajar de peso tras caso de posible da\u00f1o hep\u00e1tico","datePublished":"2025-04-15T18:59:26+00:00","mainEntityOfPage":{"@id":"https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/"},"wordCount":458,"commentCount":0,"publisher":{"@id":"https:\/\/thespanishmedia.com\/#organization"},"image":{"@id":"https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/#primaryimage"},"thumbnailUrl":"","keywords":["#Da\u00f1oHep\u00e1tico","#Danuglipron","#ensayosCl\u00ednicos","#Farmac\u00e9uticas","#IndustriaFarmac\u00e9utica","#MedicinaExperimental","#MedicinaYSalud","#NoticiasDeSalud","#Obesidad","#P\u00e9rdidaDePeso","#Pfizer","#Pfizer2025","#SaludP\u00fablica","#TratamientoObesidad","salud"],"articleSection":["Notas para Curiosos"],"inLanguage":"pt-PT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/","url":"https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/","name":"Pfizer abandona desarrollo de p\u00edldora experimental para bajar de peso tras caso de posible da\u00f1o hep\u00e1tico - The Spanish Media","isPartOf":{"@id":"https:\/\/thespanishmedia.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/#primaryimage"},"image":{"@id":"https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/#primaryimage"},"thumbnailUrl":"","datePublished":"2025-04-15T18:59:26+00:00","description":"Pfizer anunci\u00f3 el lunes que ha decidido descontinuar el desarrollo de su p\u00edldora experimental para bajar de peso","breadcrumb":{"@id":"https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/thespanishmedia.com\/pfizer-abandona-desarrollo-de-pildora-experimental-para-bajar-de-peso-tras-caso-de-posible-dano-hepatico\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/thespanishmedia.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer abandona desarrollo de p\u00edldora experimental para bajar de peso tras caso de posible da\u00f1o hep\u00e1tico"}]},{"@type":"WebSite","@id":"https:\/\/thespanishmedia.com\/#website","url":"https:\/\/thespanishmedia.com\/","name":"A M\u00eddia Espanhola","description":"Noticias en espa\u00f1ol, inmigraci\u00f3n y assentamento Canad\u00e1.","publisher":{"@id":"https:\/\/thespanishmedia.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thespanishmedia.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/thespanishmedia.com\/#organization","name":"A M\u00eddia Espanhola","url":"https:\/\/thespanishmedia.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/thespanishmedia.com\/#\/schema\/logo\/image\/","url":"https:\/\/thespanishmedia.com\/wp-content\/uploads\/2026\/08\/Logo-Horizontal.png","contentUrl":"https:\/\/thespanishmedia.com\/wp-content\/uploads\/2026\/08\/Logo-Horizontal.png","width":1840,"height":720,"caption":"The Spanish Media"},"image":{"@id":"https:\/\/thespanishmedia.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/thespanishmedia.ca","https:\/\/www.instagram.com\/thespanishmedia.ca\/","https:\/\/www.youtube.com\/@TheSpanishMedia-","https:\/\/www.tiktok.com\/@thespanishmedia"]},{"@type":"Person","@id":"https:\/\/thespanishmedia.com\/#\/schema\/person\/cdfd443208fa68f9cec21cb44a66c134","name":"A M\u00eddia Espanhola","image":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/secure.gravatar.com\/avatar\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g","caption":"The Spanish Media"},"url":"https:\/\/thespanishmedia.com\/pt\/author\/media\/"}]}},"_links":{"self":[{"href":"https:\/\/thespanishmedia.com\/pt\/wp-json\/wp\/v2\/posts\/21599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thespanishmedia.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thespanishmedia.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thespanishmedia.com\/pt\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/thespanishmedia.com\/pt\/wp-json\/wp\/v2\/comments?post=21599"}],"version-history":[{"count":0,"href":"https:\/\/thespanishmedia.com\/pt\/wp-json\/wp\/v2\/posts\/21599\/revisions"}],"wp:attachment":[{"href":"https:\/\/thespanishmedia.com\/pt\/wp-json\/wp\/v2\/media?parent=21599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thespanishmedia.com\/pt\/wp-json\/wp\/v2\/categories?post=21599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thespanishmedia.com\/pt\/wp-json\/wp\/v2\/tags?post=21599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}